Insider Selling: Amgen (NASDAQ:AMGN) SVP Sells $521,370.36 in Stock

Amgen Inc. (NASDAQ:AMGN) SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Rachna Khosla also recently made the following trade(s):

• On Tuesday, August 11th, Rachna Khosla sold 2,000 shares of Amgen stock. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00.

Amgen Stock Performance

Shares of Amgen stock opened at $415.21 on Friday. The company’s 50 day moving average price is $370.57 and its two-hundred day moving average price is $358.93. The firm has a market capitalization of $224.47 billion, a P/E ratio of 25.81, a P/E/G ratio of 3.86 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $421.79.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the prior year, the company earned $6.02 EPS. Amgen’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts forecast that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Institutional Trading of Amgen

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after buying an additional 961,975 shares in the last quarter. BlackRock Inc. lifted its holdings in Amgen by 4.8% during the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. State Street Corp boosted its stake in Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Capital World Investors boosted its stake in Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent research reports. Bank of America raised their price target on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Oppenheimer lifted their target price on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Argus decreased their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research note on Monday, July 6th. Finally, Mizuho raised their price target on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $372.39.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.